It is made explicit that additional indications for NNZ 2591 will be tested and the market informed in due course. Also that they believe it is likely to be useful for a wider variety of conditions. As far as I know this strategy has not been made explicit before - just hinted at. I presume they are considering autism. If they are doing pre clinical autism tests then I would expect this will change the prospects of NEU and how it is viewed by the industry and the market - from a biotech that targets rare conditions to a biotech that targets widespread conditions. Interesting.
Ann: Quarterly report and cash flow statement for Q4 2020, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.85 |
Change
-0.110(0.85%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.53 | $6.559M | 511.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1657 | $12.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 6303 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |